China’s Pharmaceutical Patent Litigation System: The Complete IP Enforcement Playbook for Pharma and Biotech
Why China’s Patent System Demands Your Full Attention Now China filed more than 1.5 million patent applications in 2022, making […]
Why China’s Patent System Demands Your Full Attention Now China filed more than 1.5 million patent applications in 2022, making […]
Executive Summary and Key Findings The USPTO’s Drug Patent and Exclusivity Study, produced in collaboration with the FDA at the
1. What the 505(b)(2) Pathway Actually Is (and What It Isn’t) The 505(b)(2) New Drug Application (NDA) is a hybrid
505(b)(2) Mastery: The Complete IP Strategy Guide for Drug Lifecycle Extension Read Post »
A technical deep dive for pharma IP teams, portfolio managers, R&D leads, and institutional investors Why Most Generic Drug Strategies
What Branded Generics Actually Are — and Why the Definition Matters for IP Teams The pharmaceutical industry uses ‘branded generic’
Branded Generics ROI: The Complete IP, Pricing, and Market Strategy Playbook Read Post »
Drug repurposing has a dirty secret. For every sildenafil-to-Viagra success story, there are dozens of ventures that got five years
FTO Analysis for Drug Repurposing: The Complete IP Strategy Guide Read Post »
Patent cliffs get all the attention. Divisional patents do the real work. When a blockbuster drug faces loss of exclusivity,
The full playbook of drug patent lifecycle management — and what it costs everyone else Drug companies spend roughly $2.23
How Big Pharma Stretches a 20-Year Patent Into a 40-Year Monopoly Read Post »
1. The 20-Year Myth: Why Nominal Term Is the Wrong Starting Number Ask most people in the pharmaceutical business how
Get fresh news and insights, drug patent expirations & more…